F-Prime Capital
Tenvie Therapeutics Launches with $200 Million to Revolutionize Neurological Disease Treatment
Tenvie Therapeutics, neurological diseases, small molecule therapies, Denali Therapeutics, ARCH Venture Partners, F-Prime Capital, Mubadala Capital